Biogen, Eisai and Leqembi

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...